本页面由Tiger Trade Technology Pte. Ltd.提供服务

Iovance Biotherapeutics, Inc.

2.20
-0.0500-2.22%
盘前2.200.00000.00%08:53 EST
成交量:1,061.46万
成交额:2,354.80万
市值:8.73亿
市盈率:-1.84
高:2.26
开:2.24
低:2.17
收:2.25
52周最高:8.15
52周最低:1.64
股本:3.97亿
流通股本:3.04亿
量比:1.08
换手率:3.49%
股息:- -
股息率:- -
每股收益(TTM):-1.1987
每股收益(LYR):-1.2839
净资产收益率:-53.89%
总资产收益率:-27.12%
市净率:1.24
市盈率(LYR):-1.71

数据加载中...

2024/03/19

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/04

重要事件披露

Form 8-K - Current report
2024/03/01

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/29

重要事件披露

Form 8-K - Current report
2024/02/29

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/22

重要事件披露

Form 8-K - Current report
2024/02/20

重要事件披露

Form 8-K - Current report
2024/02/20

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/09

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/26

重要事件披露

Form 8-K - Current report
2024/01/09

重要事件披露

Form 8-K - Current report
2023/12/27

重要事件披露

Form 8-K - Current report
2023/11/18

SEC问询函

Form CORRESP - Correspondence
2023/11/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/07

重要事件披露

Form 8-K - Current report
2023/10/28

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]